Background-Despite the substantial overlap of obesity and metabolic disease, there is heterogeneity with respect to cardiovascular risk. We sought to investigate preclinical differences in systolic and diastolic function in obesity, and specifically compare obese individuals with and without metabolic syndrome (MS). Methods and Results-Obese individuals without cardiac disease with (OB/MS+, n=124) and without (OB/MS−, n=37) MS were compared with nonobese controls (n=29). Diastolic function was assessed by transmitral and tissue Doppler. Global longitudinal strain (LS) and time-based dyssynchrony were assessed by speckle tracking. Both OB/MS− and OB/MS+ groups had similar ejection fraction but worse systolic mechanics as assessed by LS and dyssynchrony when compared with nonobese controls. Specifically, OB/MS− had 2.5% lower LS (SE, 0.7%; P=0.001 in multivariableadjusted analyses) and 10.8 ms greater dyssynchrony (SE, 3.3 ms; P=0.002), and OB/MS+ had 1.0% lower LS (SE, 0.3%; P<0.001) and 7.8 ms greater dyssynchrony (SE, 1.5 ms; P<0.001) when compared with controls. Obesity was associated with impaired diastolic function regardless of MS status, as evidenced by greater left atrial diameter and left ventricular mass although diastolic dysfunction was more pronounced in OB/MS+ than in OB/MS− individuals. Conclusions-Obesity is associated with subclinical differences in both systolic and diastolic function regardless of the presence or absence of MS although MS seems to be associated with worse diastolic dysfunction. When compared with controls, metabolically healthy obese had lower LS, greater dyssynchrony, and early diastolic dysfunction, supporting the notion that obesity per se may have adverse cardiovascular effects regardless of metabolic disease. (Circ Heart Fail. 2015;8:897-904.
T he prevalence of obesity has increased in Western countries during the past decades, reaching >30% among the whole population. 1 Obesity is associated with multiple metabolic abnormalities, and worsening obesity is accompanied by increased prevalence of metabolic syndrome (MS). 2 Both obesity and MS have been linked to a wide spectrum of cardiovascular morbidity and mortality, including increased risk of heart failure. [3] [4] [5] Individuals with obesity or MS are known to have changes in cardiac structure and function, including left ventricular (LV) hypertrophy and diastolic dysfunction. [6] [7] [8] [9] Previous studies have demonstrated that subclinical changes in diastolic function and LV mass both precede the development of clinical heart failure, and specifically increase the risk of heart failure with preserved ejection fraction. [10] [11] [12] [13] The effect of obesity and metabolic disease on systolic function and mechanics have been less well studied. 14 
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Despite the substantial overlap of obesity and metabolic disease, there is heterogeneity with respect to cardiovascular risk, with some studies showing favorable prognosis for metabolically healthy obese individuals. 15, 16 However, the notion of metabolically healthy obesity has recently been questioned, and it seems that obesity even in the absence of metabolic disease may be associated with cardiovascular risk and adverse outcomes. 17, 18 We sought to investigate preclinical differences in systolic and diastolic function in obesity, and specifically compare obese individuals with and without MS, in a cohort of individuals without existing cardiovascular disease. September 2015
Methods

Study Population
We recruited consecutive participants with obesity, defined as body mass index (BMI) ≥30 kg/m 2 , without existing cardiovascular disease, who attended outpatient clinic visits at Boston Medical Center. MS was defined as meeting ≥3 of the following criteria: (1) increased waist circumference (≥102 cm in men and ≥88 cm in women); (2) increased fasting triglyceride (≥150 mg/dL); (3) high blood pressure (BP, ≥130/85 mm Hg) or receiving antihypertensive therapy; (4) decreased high-density lipoprotein (HDL) cholesterol (<40 mg/dL in men and <50 mg/dL in women); (5) impaired fasting glucose (≥100 mg/dL). 19 Participants were grouped either into those with obesity and MS (OB/MS+) or 'metabolically healthy' obese, defined as obese individuals meeting ≤1 of the MS criteria with exception of increased waist circumference (OB/ MS−). We also recruited nonobese controls with BMI<30 kg/m 2 who had no other major comorbidities (hypertension, cardiovascular disease, diabetes mellitus, and hyperlipidemia). Participants with known cardiac-related signs/symptoms, LV ejection fraction <50%, or existing cardiovascular disease such as heart failure, ischemic heart disease, or valvular heart disease were excluded from the study.
Clinical Assessment
All participants underwent a comprehensive medical history and physical examination, including anthropometrics, resting BP (average of 3 consecutive measurements), and fasting blood work. Hypertension was defined as current treatment with antihypertensive therapies, systolic BP ≥140 mm Hg, or diastolic BP ≥90 mm Hg. Diabetes mellitus was defined as a fasting serum glucose level ≥126 mg/dL or current treatment for diabetes mellitus. The study was approved by the Boston University Medical Center Institutional Review Board, and all participants provided informed consent.
Transthoracic Echocardiography
All participants underwent standard transthoracic echocardiography including tissue Doppler imaging and speckle tracking (iE33; Philips, Andover, MA) with a 1-to 5-MHz transducer. Chamber dimensions including left atrial (LA), LV wall and chamber sizes, and relative wall thickness were measured. LA volumes were measured using the biplane area-length method and indexed to body surface area. LV ejection fraction was estimated by the modified Simpson rule. LV mass (g) was calculated by the formula: 1.04×[(LV end-diastole dimension+posterior wall thickness+interventricular septum thickness)3-(LV end-diastole dimension)3]-13.6 and indexed to height to the power of 2.7 (LV mass/ h 2.7 ) to correct for body habitus. 20 Measured Doppler parameters included isovolumic relaxation time, mitral E and A wave velocities, and deceleration time. Tissue Doppler measures included mitral annular early (e′) and late (a′) diastolic velocities and calculated as the mean of septal and lateral velocities, respectively. Speckle tracking analysis was performed offline using commercially available software (QLAB Software version 9 Cardiac Motion/Mechanics Quantification, Philips). In brief, global longitudinal systolic strain (LS) was the average of the negative peak LS from 17 ventricular segments obtained from the apical 4-, 3-, and 2-chamber views. Time-based dyssynchrony was defined as the SD of the electromechanical time delay from the QRS onset to peak systolic strain of the 17 LV segments. All strain analyses were performed by a single observer blinded to clinical status (Y.-C.W.). Of 222 participants who underwent strain imaging, 32 were excluded because of technical issues precluding analysis (18 had limited views and 14 had poor-quality images), leaving 190 participants for analysis. Intraobserver reproducibility was estimated in 24 randomly selected participants. The coefficient of variation was 2.2% for strain and 3.7% for time-based dyssynchrony, with intraclass correlation coefficients of 0.93 and 0.98, respectively.
Statistical Analysis
Descriptive data are listed as mean± SD for continuous variables and as a percentage for discrete variables. Differences among the 3 groups for baseline characteristics were compared using the 1-way ANOVA. Pairwise comparisons were evaluated using 2 sample t tests for continuous variables and a χ 2 test for discrete variables, with Bonferroni correction for multiple testing. For echocardiographic variables that were significantly different between groups by ANOVA, we further investigated the association of obesity and MS using multivariable linear regression, comparing study groups after adjusting for potential confounders that were selected a priori including age, sex, race, and heart rate. We additionally adjusted for individual components of the MS including systolic BP, fasting glucose, waist circumference, and the triglyceride/HDL cholesterol ratio and examined each component individually in exploratory analyses. For all tests, a 2-tailed value of P<0.05 was considered statistically significant.
In sensitivity analyses, multivariable regression models were repeated after exclusion of individuals with hypertension or diabetes mellitus. In exploratory analyses, we used forward and backward selection models to investigate the association of metabolic risk factors as continuous variables (systolic BP, waist circumference, fasting glucose, HDL cholesterol, and log-triglyceride level) with strain measures among obese individuals. The linear regression model was fitted with LS as the response variable, and age and sex were retained. Backward selection was performed with eligible covariates removed sequentially based on the least significant term using a significance level of P≥0.05, and the model re-estimated after removal. We repeated the same models using forward selection. Specifically, eligible covariates were entered sequentially using a significance level of P<0.05, with the most significant term added first and re-estimated. All analyses were performed using the Stata 11.2, and forward and backward selection models were fitted using the stepwise command (StataCorp, College Station, TX).
Results
A total of 124 obese individuals with MS (OB/MS+, 45±11 years, 77% women), and 37 metabolically healthy obese participants (OB/MS−, 39±11 years, 86% women) were compared with 29 nonobese controls (43±12 years, 69% women). Baseline clinical characteristics are displayed in Table 1 . Among obese individuals, 42% were severely obese (BMI>40 kg/m 2 ), and there was no significant difference in BMI between participants with or without MS (P=0.54). Among nonobese individuals, half were overweight (52% with BMI≥25 but <30 kg/m 2 ). Within metabolically healthy obese individuals, none had diabetes mellitus, and the triglyceride/HDL ratio was similar to that of healthy controls (1.8±1.0 versus 1.6±1.0, respectively; P>0.99), whereas the triglyceride/HDL ratio in the OB/MS+ group was >2.5-fold higher (4.2±3.7; P<0.001) than in the OB/MS−. Traditional cardiovascular risk factors were most prevalent in OB/MS+, followed by OB/MS−, and absent in healthy controls ( Table 1 ).
Measures of Systolic and Diastolic Functions in Obesity With or Without MS
Although LV dimensions were similar between groups, obesity was associated with significantly greater LV mass and LA diameter regardless of MS status, and there was no difference in LV mass or LA diameter in OB/MS− versus OB/MS+ groups ( Table 2 ). For measures of diastolic function, E/A ratio and mitral e′ were lowest, and E/e′ ratio highest in the OB/ MS+ group, whereas these features were largely intermediate or similar to healthy controls in the OB/MS− group (Table 2) . For example, mitral e′ was lowest in OB/MS+ (9.2±2.3 cm/s; P<0.001) when compared with OB/MS-, whereas there was no significant difference between OB/MS− and healthy controls (11.4±2.4 and 11.4±3.0 cm/s, respectively, P>0.99 for OB/MS− versus controls).
With regard to systolic function, there was no detectable difference in LV systolic function as measures by LV ejection fraction between groups (P=0.54, ANOVA). However, systolic myocardial mechanics were impaired in obese individuals as evidenced by a graded decrease of LS, with the lowest LS in the OB/MS+ group. Specifically, LS was −18.5±2.8% in OB/MS+, −19.1±2.6% in OB/MS−, and −20.8±2.5% in controls (P<0.001, ANOVA). Similarly, time-based dyssynchrony seemed worse in obese individuals with and without MS than in healthy controls (55±14 ms in OB/MS+, 49±13 in OB/MS−, and 40+11 in controls; P<0.001; Table 2 ). Finally, mitral annular plane systolic excursion (s′) as measured by tissue Doppler was significantly different between groups (P=0.006, ANOVA, Table 2 ). Evidence of LV remodeling and differences in both systolic and diastolic functions in metabolically healthy obese individuals compared with healthy controls persisted after adjusting for other potential confounders, including age, sex, race, and heart rate (Table 3) . Specifically, obesity in the absence of MS was associated with greater LA diameter, LV end-diastolic dimension, LV end-systolic dimension, LV mass/h 2.7 , mitral A-flow, and dyssynchrony, and lower mitral E/A and global LS. With regards to systolic mechanics, metabolically healthy obese individuals had a 2.5% lower LS and 11 ms greater time-based dyssynchrony compared with nonobese controls. Furthermore, when comparing obese individuals with and without MS, those with MS had greater relative wall thickness, lower mitral e′, and higher mitral E/e′ compared with metabolically healthy obese individuals (Table 3) .
Differences in Systolic and Diastolic Functions in Obesity With and Without MS Are Independent of Potential Clinical Confounders
After additionally accounting for individual components of MS, including systolic BP, fasting glucose, waist circumference, and triglyceride/HDL ratio, the association of obesity with greater LA diameter, LV mass, and time-based dyssynchrony remained robust although differences in strain were attenuated (Table 4 ). In obese individuals with MS, similar differences in systolic mechanics and diastolic function were seen as in the OB/MS− group than in the controls after accounting for potential clinical confounders. In addition, further evidence of differences in other diastolic parameters and LV remodeling was apparent, including greater relative wall thickness, longer isovolumic relaxation time, lower mitral e′, and higher mitral E/e'. Most differences in systolic and diastolic functions between obese individuals with MS and controls persisted, including LA diameter, LV mass, E/A ratio, mean e′, and dyssynchrony. When comparing obese individuals with and without MS, differences in LV dimensions and mean e′ persisted (Table 4 ). In exploratory analyses examining individual components of MS and their effect on differences in global LS, we found the greatest attenuation with the addition of waist circumference when comparing OB/MS+ and nonobese control groups. For OB/MS− compared with controls, differences in strain were attenuated with both the addition of waist circumference and systolic BP ( Table I in 
Alterations in Systolic and Diastolic Functions Persist in the Absence of Hypertension or Diabetes Mellitus
In sensitivity analyses, we excluded individuals with hypertension (n=96) from the analysis ( Table II in the Data Supplement). In the absence of hypertension, both diastolic function and systolic mechanics as assessed by time-based dyssynchrony remained impaired in obese individuals regardless of MS status when compared with controls, even after multivariable 
Correlates of Strain and Dyssynchrony
In exploratory analyses among obese individuals, we used stepwise models to examine metabolic risk factors as continuous variables in relation to strain parameters, with both forward and backward selection yielding the same results. Higher systolic BP, male sex, and higher waist circumference were associated with lower global LS. Specifically, every 15-cm increase in waist circumference was associated with a 0.5% lower LS (β=0.5; SE, 0.1; P=0.001). Similarly, age, fasting glucose, waist circumference, and systolic BP were all associated with greater time-based dyssynchrony. Every 15-cm increase in waist circumference was associated with a 2.8-ms increase in dyssynchrony (β=2.8; SE, 0.7; P<0.001).
Discussion
We demonstrated that obesity per se was associated with impaired systolic mechanics as reflected by LS and dyssynchrony, regardless of the presence or the absence of MS. Furthermore, subclinical changes in systolic mechanics were detected in the absence of any impairment in LV ejection fraction. In individuals with MS, this subclinical impairment of systolic function occurred concomitantly with altered diastolic function. In contrast, diastolic dysfunction seemed to be less pronounced in the metabolically healthy obese. These subclinical alterations in systolic and diastolic functions suggest that cardiovascular effects of obesity and MS are manifest even in the absence of overt cardiovascular disease. Detection of early myocardial dysfunction may help identify individuals at risk for development of subsequent clinical heart failure, 21 and may guide future preventive strategies.
Few studies have examined systolic mechanics in obesity. Severe obesity was previously associated with lower regional myocardial systolic strain and strain rate when compared with healthy controls. 22 Obesity was not further subclassified into those with and without MS in this study, and not unexpectedly, the obese group had significantly higher insulin resistance than the controls. Interestingly, insulin resistance was strongly correlated with systolic mechanics. 22 Similarly, MS was associated with lower LS and strain rate, as well as LV dyssynchrony as assessed by speckle tracking in nondiabetic participants of the RESOLVE (Reverse Metabolic Syndrome by Lifestyle and Various Exercises) study. Differences in systolic mechanics correlated strongly with abdominal obesity and markers of systemic inflammation. 14, 23 More recently, obesity in early adulthood was associated with LV strain measures in the Coronary Artery Risk Development in Young Adults Study. 24 Our findings are consistent with these previous studies, confirming both lower LS and greater dyssynchrony in obese individuals with MS. Importantly, we now extend these findings to the metabolically healthy obese in our carefully phenotyped cohort, demonstrating worse strain and greater dyssynchrony in obesity even in the absence of MS. A recent small study in 10 obese middle-aged nondiabetic men demonstrated improvement in systolic strain and dyssynchrony measures, as well as diastolic function with exercise training, suggesting that these functional changes are potentially reversible. 25 Notably, after accounting for individual components of MS, the association with LS was attenuated; however, the association of obesity and greater dyssynchrony persisted. These findings suggest that the observed differences in strain could be explained by components of MS; however, that MS in and of itself does not have a discernible effect beyond its individual components.
Numerous studies have demonstrated diastolic dysfunction in metabolic disease, which seems to be independent of LV hypertrophy, 8, [26] [27] [28] and our results support these observations. Fewer studies have examined the effect of metabolically healthy obesity on diastolic function; Pascual et al 29 studied 31 obese individuals (mean age, <30 years) without hypertension, diabetes mellitus, or dyslipidemia. Although there was no difference in mitral E/A between the obese and the normal group, the obese had a relatively higher A-flow velocity. Another study that examined 29 obese participants (mean age, 49 years) without MS showed that isolated obesity was associated with lower e′ and higher E/e′ when compared with the controls. 30 We did not find a significant difference in e′ or E/e′ ratio between metabolically healthy obese and controls although we did find greater LA diameter, LV mass, and lower E/A ratio, indicating early changes in diastolic function in the obese even in the absence of MS. This suggests a potential intermediate phenotype of subclinical cardiovascular disease in the metabolically healthy obese. Because age may not only influence diastolic function but also serve as a potential indicator of the duration of obesity, age differences could contribute to the variable spectrum of diastolic dysfunction in these previous studies. 31 Although earlier studies supported the concept of metabolically healthy obesity, 15, 16 more recent studies have demonstrated higher prevalence of subclinical coronary atherosclerosis, 17 greater risk of cardiovascular events, 18 and specifically increased risk of future heart failure 32 in metabolically healthy obese when compared with metabolically healthy normal weight individuals. Our findings further support preclinical changes in both systolic and diastolic functions even in the metabolically healthy obese, contributing to the mounting evidence that "healthy obesity is ... a myth," 33 and that obesity per se, in the absence of metabolic disease, may have adverse cardiovascular effects. Interestingly, weight gain has been associated with worsening LV diastolic stiffness, and conversely, weight loss with improved reduced arterial stiffness, suggesting that modulation of weight may impact cardiovascular disease. 34, 35 Several limitations deserve mention. First, the definition of metabolically healthy obese has not been consistent in the literature. 17, 18, 32, 36 Our definition was consistent with a more conservative approach used in some previous studies 37 and included individuals with 0 to 1 traditional MS risk factors in the metabolically healthy obese group. The triglyceride/ HDL ratio in the metabolically healthy obese was similar to healthy controls, suggesting that this group did represent obesity largely in the absence of metabolic disease; however, it is possible that alterations in systolic mechanics are confounded by other risk factors in the obese. We adjusted for potential clinical confounders, and results were also relatively robust in sensitivity analyses excluding hypertension and diabetes mellitus; however, residual confounding remains a possibility. One such confounder may be physical activity and fitness, which were not assessed in our study, and may account for differences between metabolically healthy and unhealthy individuals. 38 In the setting of our modest sample size, multivariable adjustment may be limited because of concerns of overfitting statistical models. Given that ours is an observational crosssectional study, causal inferences cannot be drawn, and the clinical implications of these subclinical changes in cardiac structure and function are not known. Finally, epicardial adipose tissue was not measured and may lend further insights into the cardiovascular effects of obesity, metabolic disease, and adiposity in future studies.
In summary, we found that obesity was associated with subclinical differences in both systolic and diastolic function regardless of the presence or the absence of MS. Although abnormalities were more pronounced in those with MS, we specifically observed lower global LS, greater dyssynchrony, and early diastolic dysfunction in the metabolically healthy obese, supporting the notion that obesity may have adverse cardiovascular effects regardless of metabolic disease. Additional studies are needed to confirm these findings and to examine the impact of obesity and potential weight management strategies on cardiovascular risk, and specifically, the development of heart failure.
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